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background
 
Currently, there is no effective intervention for a primary cytomegalovirus (CMV) infec-
tion during pregnancy.
 
methods
 
We studied pregnant women with a primary CMV infection. The therapy group com-
prised women whose amniotic fluid contained either CMV or CMV DNA and who were
offered intravenous CMV hyperimmune globulin at a dose of 200 U per kilogram of ma-
ternal weight. A prevention group, consisting of women with a recent primary infection
before 21 weeks’ gestation or who declined amniocentesis, was offered monthly hyper-
immune globulin (100 U per kilogram intravenously).
 
results
 
In the therapy group, 31 women received hyperimmune globulin, only 1 (3 percent) of
whom gave birth to an infant with CMV disease (symptomatic at birth and handicapped
at two or more years of age), as compared with 7 of 14 women who did not receive hy-
perimmune globulin (50 percent). Thus, hyperimmune globulin therapy was associ-
ated with a significantly lower risk of congenital CMV disease (adjusted odds ratio,
0.02; 95 percent confidence interval, ¡
 
∞
 
 to 0.15; P<0.001). In the prevention group,
37 women received hyperimmune globulin, 6 (16 percent) of whom had infants with
congenital CMV infection, as compared with 19 of 47 women (40 percent) who did not
receive hyperimmune globulin. Thus, hyperimmune globulin therapy was associated
with a significantly lower risk of congenital CMV infection (adjusted odds ratio, 0.32; 95
percent confidence interval, 0.10 to 0.94; P=0.04). Hyperimmune globulin therapy sig-
nificantly (P<0.001) increased CMV-specific IgG concentrations and avidity and de-
creased natural killer cells and HLA-DR+ cells and had no adverse effects.
 
conclusions
 
Treatment of pregnant women with CMV-specific hyperimmune globulin is safe, and
the findings of this nonrandomized study suggest that it may be effective in the treat-
ment and prevention of congenital CMV infection. A controlled trial of this agent may
now be appropriate.
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ytomegalovirus (cmv) infection is
 
a common and serious infection occur-
ring in approximately 1 percent of all ne-
onates.
 
1-3
 
 Congenital CMV infection is symptom-
atic in about 10 percent of the infected neonates and
is associated with clinically significant neurologic
sequelae in almost half of them. In addition, neuro-
logic defects will eventually develop in 8 to 13 per-
cent of neonates with asymptomatic infection.
 
1-3
 
Among women with a primary infection during
pregnancy, the rate of fetal infection is approximate-
ly 40 percent.
 
1,3,4
 
 Although prenatal diagnosis of
congenital infection is possible, no prenatal ther-
apy is currently available.
Following the favorable outcome of the infu-
sion of CMV-specific hyperimmune globulin in a
fetus with symptomatic CMV infection,
 
5
 
 we per-
formed a prospective study of hyperimmune glob-
ulin for the treatment or prevention of fetal CMV
infection.
 
patients and protocol
 
A prospective study was performed from 1995 to
2003. Pregnant women who had a primary CMV
infection during or a few months before pregnan-
cy were eligible, as were those who had undergone
amniocentesis that revealed CMV in amniotic fluid.
Given the likely safety of hyperimmune globulin, the
efficacy of immune globulin in animal models, and
the off-protocol availability of hyperimmune glob-
ulin, none of three ethics committees approved the
use of a randomized protocol but did approve the
administration of hyperimmune globulin in preg-
nant women with a confirmed primary CMV infec-
tion who had provided written informed consent.
We enrolled 157 pregnant women with primary
CMV infection in eight Italian cities (127 in Rome,
17 in Genoa, 8 in Perugia, and 1 each in five other
cities) (Fig. 1). Serologic testing was initiated by ob-
stetricians, who routinely screened their patients
and then referred women for inclusion in the study.
A total of 148 women with no symptoms were iden-
tified on the basis of serologic screening, 8 wom-
en were identified on the basis of serologic testing
after an illness compatible with CMV infection,
and 1 woman was identified on the basis of serolog-
ic testing conducted after fetal ultrasonography
showed abnormal results. All eligible subjects were
enrolled. After enrollment, clinical, ultrasonograph-
ic, immunologic, and virologic evaluations were per-
formed monthly.
Serologic testing was performed on serum sam-
ples obtained at the first obstetrical visit and every
one to three months thereafter (mean, six weeks).
Primary infection was defined by seroconversion
in 131 women who were previously CMV-seroneg-
ative, by the presence of CMV-specific IgM antibod-
ies in 4 women, and by the presence of CMV-specific
IgM antibodies and very low but increasing concen-
trations of CMV-specific IgG antibodies with very
low CMV-specific IgG avidity (no more than 25 per-
cent) in 22 women. The four women with CMV-spe-
cific IgM antibodies (identified at six, six, seven, and
nine weeks of pregnancy) had increasing concentra-
tions of CMV-specific IgG antibodies and increas-
ing CMV-specific IgG avidity and may have become
infected up to three months before conception.
Pregnant women were placed in one of two
groups. The therapy group consisted of pregnant
women who had had a primary infection more than
6 weeks before enrollment who were offered am-
niocentesis as soon as safely feasible (usually at
20 weeks’ gestation or more). If the amniotic flu-
id contained either CMV DNA on the basis of a po-
lymerase-chain-reaction (PCR) assay or CMV on
the basis of culture results, intravenous hyperim-
mune globulin was offered at a dose of 200 U per
kilogram of maternal weight. Additional intrave-
nous doses and intra–umbilical-cord or intraam-
niotic doses (400 U per kilogram of fetal weight)
were used only in the event of ultrasonographic ev-
idence of persistent fetal involvement. Women with
CMV-positive amniotic fluid who declined to receive
hyperimmune globulin infusions were followed as
a comparison group. A total of 79 women under-
went amniocentesis, 24 of whom had no evidence
of CMV in amniotic fluid. These 24 women were
ineligible for the study, but their infants were eval-
uated at birth.
The prevention group comprised women who
had not undergone amniocentesis before or at en-
rollment. Reasons for not undergoing amniocen-
tesis were a primary infection within 6 weeks be-
fore enrollment and a pregnancy of less than 20
weeks’ gestation (making the detection of CMV
in amniotic fluid unlikely) or a woman’s declining
to undergo the procedure, regardless of the inter-
val between a primary infection and enrollment.
All women were offered intravenous hyperimmune
globulin at a dose of 100 U per kilogram every
c
methods
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;13
 
www.nejm.org september 
 
29
 
, 
 
2005
 
The
 
 new england journal 
 
of
 
 medicine
 
1352
 
month until delivery. Monthly treatment was se-
lected for this group because of the unknown in-
fection status of their fetuses and thus the desire
to sustain antibody concentrations until delivery.
Because of the use of multiple doses, a lower dose
was selected to reduce costs. Pregnant women who
declined to receive hyperimmune globulin were
used as a comparison group.
Twenty-eight women (10 in the therapy group
and 18 in the prevention group), none of whom re-
ceived hyperimmune globulin, were excluded from
follow-up when their pregnancies were aborted
(27 elective and 1 spontaneous). The rate of infec-
tion among the fetuses of the 18 women who abort-
ed in the prevention group was not determined.
Neonatal evaluations included testing of urine
for CMV by two weeks of age; physical examina-
tion; blood-cell and platelet count; measurement
of aminotransferase, bilirubin, and creatinine con-
centrations; ophthalmoscopy; cerebral and ab-
dominal ultrasonography; and brain-stem auditory
evoked responses. Among fetuses with suspected
neurologic involvement, cerebrospinal fluid was ob-
tained and electroencephalography, cerebral com-
puted tomography, and magnetic resonance imag-
ing were performed.
Symptomatic congenital CMV disease was de-
fined by fetal or infant death or by neurologic in-
volvement, including microcephaly (head circum-
ference below the 5th percentile for gestational
age
 
6
 
), periventricular calcifications, cerebral dyspla-
sias, seizures in an infant with CMV DNA in cerebro-
spinal fluid, ventricular and subependymal abnor-
malities, chorioretinitis, or auditory impairment.
Intrauterine growth restriction was defined by head
and abdominal circumferences that were below the
10th percentile for fetuses of similar age.
 
7
 
 CMV dis-
ease at two years of age or older was defined by
mental retardation (IQ below 70) or motor delay, or
both, and auditory or visual impairment. The Gesell,
Bayley, and Stanford–Binet scales were used for
evaluation. During the first two years of life, the chil-
dren’s hearing was assessed by brain-stem audito-
ry evoked responses. The threshold for normal hear-
 
Figure 1. Enrollment and Outcomes.
181 Pregnant women identified
with confirmed primary CMV
infection
79 Underwent amniocentesis
before or at enrollment and >6 wk
after maternal seroconversion
102 Enrolled who did not
undergo amniocentesis
55 Women with
CMV-positive
amniotic fluid enrolled
10 Elected to have
an abortion, no
hyperimmune
globulin
14 Elected not
to receive
hyperimmune
globulin
31 Elected to
receive
hyperimmune
globulin
(200 U/kg)
37 Elected to receive
hyperimmune globulin
(100 U/kg) monthly
until delivery
65 Elected not to
receive hyperimmune
globulin
47 Gave birth
18 Had an
abortion
37 Gave birth
24 Women with 
CMV-negative
amniotic fluid ineligible
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;13
 
www.nejm.org september 
 
29, 2005
 
passive immunization against cmv during pregnancy
 
1353
 
* HIG denotes hyperimmune globulin, and NA not applicable.
† Groups were compared by Fisher’s exact test or by Wilcoxon’s rank-sum test.
‡ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points of the range was used 
 
to estimate the time of maternal infection.
 
Table 1. Baseline Characteristics of the Therapy and Prevention Groups.*
Characteristic Therapy Group (N=45) Prevention Group (N=84)
 
Received HIG
(N=31)
No HIG
(N=14) P Value†
Received HIG
(N=37)
No HIG 
(N=47) P Value†
Maternal age at enrollment (yr) 0.72 0.32
Median 29 27 30 29
Interquartile range 25–32  26–32 28–33 27–32
No. of primary maternal infections 0.21 0.38
Identified by ultrasonography 1 0 0 0
Identified by maternal screening 27 14 36 43
Identified by maternal symptoms 3 0 1 4
No. of primary maternal infections identified by IgM 
antibodies alone
2 2 0.58 0 0 ND
Wk of gestation at maternal infection‡ 0.79 <0.01
Median 12 11 14 20
Interquartile range 8–15 9–18 8–16 14–26
No. of fetuses with ultrasonographic evidence 
of disease
15 7 0.92 NA NA NA
Copies of CMV DNA in amniotic fluid (¬10
 
4
 
) 0.15
Median 17 28 NA NA NA
Interquartile range 1–37 13–85 NA NA
No. of women with CMV-positive amniotic fluid 0.47 NA NA NA
By PCR alone 11 5
By culture alone 3 0
By PCR and culture 17 9
Wk of gestation for HIG administration NA NA
Median 24 NA 19 NA
Interquartile range 22–27 NA 16–23 NA
Doses of HIG per woman NA NA
Median 1 NA 5 NA
Interquartile range 1–1 NA 4 – 6 NA
No. of women given intra–umbilical-cord or 
intraamniotic HIG (or both)
9 NA NA NA NA NA
Fetal infection identified (wk of gestation) 0.14 NA
Median 21 23 NA NA
Interquartile range 19–25 20–32 NA NA
Time between maternal infection and HIG admin-
istration (wk)
NA NA
Median 13 NA 6 NA
Interquartile range 10–15 NA 5–9 NA
Time between fetal diagnosis and HIG admin-
istration (wk)
NA NA
Median 2 NA NA NA
Interquartile range 1–4 NA NA NA
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ing was defined as 0 to 20 dB. Abnormal responses
were defined as mild (threshold, 21 to 45 dB), mod-
erate (threshold, 46 to 70 dB), or severe (threshold,
at least 71 dB). 
Each neonate was evaluated by a neonatologist,
and follow-up of all neonates was done by a single
physician.
 
cmv hyperimmune globulin
 
CMV hyperimmune globulin (Cytotect Biotest) has
a half-life of approximately 22 days, has been used
safely in other studies, and has antiviral and immu-
nomodulatory effects.
 
8-12
 
 The mean titer of IgG an-
tibodies against CMV glycoprotein B was 1:409,600,
and the mean IgG avidity was 75.9 percent. The in-
fusion rate was 25 U per minute for 30 minutes and
then 50 U per minute until the calculated dose was
administered.
 
virologic methods
 
CMV was isolated by means of a shell vial. CMV
DNA was detected with the use of DNA extraction
and nested PCR.
 
13
 
 To determine the number of
genomic copies, competitive quantitative PCR was
performed with the use of CMV-ibridoquant (Am-
plimedical Bioline).
 
antibody detection
 
CMV-specific IgG and IgM antibodies were detect-
ed by an enzyme immunoassay kit (Radim). Dupli-
cate serum samples were tested. Antibody concen-
trations (in units per milliliter) were calculated from
a calibration curve. CMV-specific IgG avidity was
measured with a kit from Bouty (Sesto). On the ba-
sis of published data and data from the manufac-
turer, avidities of less than 25 percent indicated an
infection within the previous three months.
 
14
 
immunologic studies
 
Immunologic studies were performed in a sub-
group of women who received hyperimmune glob-
ulin, before and after infusions, and in untreated
women at enrollment and after two months. The
cytotoxic activity of natural killer cells in response
to CMV-infected cells was determined on K562
cells labeled with chromium-51 by means of a four-
hour 
 
51
 
Cr-release assay and was expressed as a spe-
cific percentage of cytotoxicity at various effector-
to-target ratios (100:1, 50:1, 25:1, and 12.5:1).
 
15
 
The percentage and number of CD3+ T cells, CD4+
(helper–inducer) T cells, CD8+ cells (cytotoxic sup-
pressor lymphocytes), CD16+56+ cells (natural kill-
er cells), CD19+ B cells, and HLA-DR+ cells (acti-
vated lymphocytes, monocytes, and macrophages)
in blood were determined by flow cytometry.
 
15,16
 
statistical analysis
 
Fisher’s exact test or Wilcoxon’s rank-sum test was
used for univariate analysis. Where appropriate, a
t-test was used on log-transformed data. An exact
logistic-regression analysis determined the fac-
tors associated with congenital infection or disease
(LogXact, version 4.0.2, Cytel Software). Using the
methods of Hosmer and Lemeshow, we evaluated
unadjusted odds ratios for potential inclusion in a
model.
 
17
 
 All those with an initial P value of less than
0.2 were included in the multivariate model.
 
therapy group
 
The therapy group consisted of 31 women who re-
ceived at least one infusion of hyperimmune glob-
ulin within 1 to 9 weeks (mean, 3.2 weeks) after the
diagnosis of fetal infection by amniocentesis and
14 women who declined to receive hyperimmune
globulin. The baseline variables in Table 1 were sim-
ilar in the two subgroups of women. Because of ul-
trasonographic evidence of persistent fetal disease,
nine women (29 percent) received one or two addi-
tional intravenous infusions two to six weeks apart
and intra–umbilical-cord or amniotic infusions of
hyperimmune globulin or both (Tables 1 and 2).
Of the 31 women receiving hyperimmune glob-
ulin in the therapy group (15 of whom were carry-
ing a fetus with ultrasonographic evidence of CMV
infection), only 1 delivered an infant with CMV dis-
ease, whereas 7 of 14 women who did not receive
hyperimmune globulin had affected infants. For in-
fants with ultrasonographic evidence of disease be-
fore birth, the signs and symptoms of fetal disease,
disease at birth, and outcome at two years of age or
older are shown in Table 2. Each infant with a symp-
tomatic infection at birth had disease at two years
of age, and each had ultrasonographic evidence of
fetal disease. No infant without ultrasonographic
evidence of fetal disease had symptoms at birth or
subsequently had sequelae.
Table 3 lists potential predictors of congenital
disease among mothers in the therapy group. A
logistic-regression model showed that two predic-
tors were associated with a significantly reduced or
increased risk of congenital disease. These were re-
ceipt of hyperimmune globulin (adjusted odds ra-
results
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tio, 0.02; 95 percent confidence interval, ¡
 
∞
 
 to
0.15; P<0.001) and the presence of fetal disease
(adjusted odds ratio, 60.0; 95 percent confidence
interval, 5.5 to 
 
∞
 
; P<0.001), respectively. We re-
peated the logistic-regression model after exclud-
ing data on seven women whose diagnosis of pri-
mary infection was based solely on the presence
of CMV-specific IgM antibodies in their serum or
whose infants were not infected at birth. After
these exclusions, the receipt of hyperimmune glob-
ulin remained a significant predictor of a reduced
risk of neonatal disease (adjusted odds ratio, 0.03;
95 percent confidence interval, ¡
 
∞
 
 to 0.27; P=0.001)
and the presence of fetal disease remained a sig-
nificant predictor of an increased risk (adjusted odds
ratio, 42.0; 95 percent confidence interval, 38.8 to
 
∞
 
; P=0.001).
 
prevention group
 
The prevention group consisted of 37 women treat-
ed with monthly infusions of hyperimmune glob-
ulin 2 to 11 weeks (mean, 6.6) after presumed sero-
conversion; the number of infusions ranged from
2 to 7 (mean, 4.8). Five women missed infusions in
the third trimester. Also in this group were 47 preg-
nant women who did not receive hyperimmune
globulin. Of the 37 women who received hyperim-
mune globulin, 6 (16 percent) had infants with con-
genital infection. This rate was significantly lower
(P=0.02) than the 40 percent rate among the wom-
en who did not receive hyperimmune globulin (19
of 47).
Significantly associated with the receipt of hy-
perimmune globulin was a younger gestational age
at maternal infection, as compared with that among
 
* HIG denotes hyperimmune globulin, and NI not included in multivariate model.
† Either Fisher’s exact test or Wilcoxon’s rank-sum test was used for univariate comparisons. 
‡ Exact logistic regression was used for the multivariate comparison.
§ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points 
 
of the range was used to estimate the time of maternal infection.
 
Table 3. Univariate and Adjusted Multivariate Logistic-Regression Analysis of Possible Predictors of Symptomatic 
Congenital CMV Disease in the Therapy Group.*
Predictor
Symptomatic 
Group
(N=8)
Asymptomatic 
Group
(N=37)
Univariate 
P Value†
Multivariate 
P Value‡
 
No. of infants whose mothers received HIG 1 30 <0.001 <0.001
No. of fetuses with ultrasonographic evidence 
of disease before HIG therapy
8 14 0.002 <0.001
No. of copies of CMV DNA in amniotic fluid (¬10
 
4
 
)
Median 29.0 5.5 0.03 0.40
Interquartile range 21–92 1–36
No. of primary infections 0.44 NI
Identified by ultrasonography 0 1
Identified by maternal screening 8 33
Identified by maternal symptoms 0 3
Maternal age at enrollment (yr)
Median 26 29 0.45 NI
Interquartile range 25–31 26–33
Weeks of gestation at maternal infection§
Median 9 12 0.33 NI
Interquartile range 7–15 10–16
No. of women receiving intra–umbilical-cord or
intraamniotic HIG (or both)
1 8 1.0 NI
No. of infants who shed CMV at birth 8 31 0.58 NI
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untreated women (Table 1). This occurred because
women who declined to undergo amniocentesis
were also more likely to decline hyperimmune glob-
ulin therapy. Women who were at 21 weeks of ges-
tation or more at infection constituted 47 percent
of the women declining hyperimmune globulin but
only 13 percent of those receiving hyperimmune
globulin. Thus, the prevention group contained two
subgroups, those infected before 21 weeks’ gesta-
tion (when amniocentesis was less likely to be pre-
dictive) and those infected at 21 weeks’ gestation or
more but who declined amniocentesis. The differ-
ence in infection rates between these two groups
was not significant (P=0.20) (Table 4).
A logistic-regression model identified only one
predictor associated with a significant reduction
in the risk of congenital infection (Table 4) — receipt
of hyperimmune globulin (adjusted odds ratio,
0.32; 95 percent confidence interval, 0.10 to 0.94;
P=0.04). For women receiving hyperimmune glob-
ulin, there was no association between congenital
infection and the average number of doses of hy-
perimmune globulin received, gestational age at the
time of treatment, or the interval between infection
and receipt of hyperimmune globulin (Table 4).
In the prevention group, three women who did
not receive hyperimmune globulin became infect-
ed at 9, 10, and 18 weeks’ gestation, and gave birth
to infants with severe symptomatic infections. None
of the infants born to women who received hyper-
immune globulin had symptoms at birth. There was
no significant difference in the rates of symptom-
atic infection between infants of treated women and
infants of untreated women in the prevention group.
Finally, we considered all women. In the pre-
vention group, 47 women did not receive hyper-
immune globulin, 19 of whom had infected neo-
nates; in the therapy group, 55 women (including
10 who had an abortion) either did not receive hy-
perimmune globulin or received it after CMV dis-
ease was diagnosed in their fetus and 24 women
had CMV-negative amniotic fluid, 3 of whom had
infected but asymptomatic infants. These 126 wom-
en had a mean (±SD) gestational age at infection
of 14.3±7 weeks, and 56 percent (71 women) had
infected newborns. This rate was significantly high-
er (odds ratio, 0.15; 95 percent confidence inter-
val, 0.06 to 0.38; P<0.001) than the 16 percent rate
(6 of 37) among women who received hyperim-
mune globulin, who were at a mean of 13.2±5.5
weeks of gestation at infection. Overall, CMV dis-
ease occurred in 28 percent (10 of 36) of the infants
infected in utero whose mothers had a mean gesta-
tional age at infection of 16±9 weeks and who did
not receive hyperimmune globulin. This rate was
significantly higher (odds ratio, 0.07; 95 percent
confidence interval, 0.01 to 0.60; P=0.003) than the
2.7 percent rate among the infants of women who
received hyperimmune globulin (in the prevention
and therapy groups) and who had a mean gesta-
tional age at infection of 14±4 weeks; in this group,
CMV disease developed in only 1 of 37 infants in-
fected in utero.
 
immunologic studies
 
We performed immunologic assays in women avail-
able for follow-up evaluations in Rome. Treatment
with hyperimmune globulin in prevention or therapy
doses was significantly associated with increased
CMV-specific IgG concentrations and IgG avidity
in serum after infusions (measured within 30 min-
utes after infusion in 24 patients and within six days
in 8 patients) to values similar to those present at
delivery (Table 5). Women receiving hyperimmune
globulin had CMV-specific IgG concentrations and
avidities at delivery similar to those among untreat-
ed women (Table 5).
The number and percentage of immune cells
were measured at enrollment and about eight
weeks after hyperimmune globulin infusion in 26
women and at enrollment and eight weeks later
in 21 untreated women. There were no significant
changes in values in the untreated women. Wom-
en who received hyperimmune globulin had a sig-
nificant decrease of approximately 33 percent of
the percentage of the total natural killer cells and
HLA-DR+ cells and of the natural killer cell activity
and a 40 percent decrease in the absolute number
of HLA-DR+ and natural killer cells but no signifi-
cant changes in CD3+, CD4+, CD8+, or CD19+ re-
sponses.
 
adverse events
 
No adverse events were associated with hyperim-
mune globulin infusions.
Our observations are consistent with the natural
history of CMV infection and pregnancy. For wom-
en infected before conception (who are seroposi-
tive), the rate of transmission of CMV from mother
to fetus usually ranges from 0.5 to 2 percent.
 
1,18
 
However, for women with a primary infection dur-
discussion
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ing pregnancy, reported rates of maternal-to-fetal
transmission range from 40 to 50 percent.
 
1,3,4
 
 Over-
all, transmission occurred among 56 percent of
women with a primary infection and 16 percent of
those receiving hyperimmune globulin.
The highest rate of symptomatic congenital in-
fection and sequelae — about 25 percent — occurs
among infected infants whose mothers had a pri-
mary infection during pregnancy.
 
19
 
 The rate of CMV
disease among infected infants of seropositive
mothers is 8 percent or less.
 
19
 
 We observed CMV
disease in 28 percent of congenitally infected in-
fants whose mothers did not receive hyperimmune
globulin. This rate is compatible with previous ob-
servations. Among the 37 congenitally infected in-
fants of women who received hyperimmune globu-
lin, only 1 (3 percent) had CMV disease.
Neonatal-transfusion studies first showed that
antibodies against CMV were protective against
CMV disease.
 
20,21
 
 Symptomatic CMV infections de-
 
* HIG denotes hyperimmune globulin, and ND not done.
† Either Fisher’s exact test or Wilcoxon’s rank-sum test was used for the univariate comparisons. 
‡ Exact logistic regression was used for the multivariate comparison.
§ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points 
of the range was used to estimate the time of maternal infection.
 
¶Plus–minus values are means ±SD.
 
Table 4. Univariate and Adjusted Multivariate (Logistic-Regression) Analysis of Possible Predictors of Congenital CMV 
Infection for the Prevention Group.*
Predictor Infected Group 
Uninfected 
Group 
Univariate 
P Value†
Multivariate 
P Value‡
 
All women in the prevention group 25 59
Infants whose mothers received HIG — no. (%) 6 (24) 31 (52) 0.02 0.04
Time of primary infection — no. of women§ 0.20 0.49
<21 weeks of gestation 14 43
≥21 weeks of gestation 11 16
Maternal age at enrollment — yr 0.78 ND
Median 30 29
Interquartile range 27–32 27–33
No. of primary infections 0.62 ND
Identified by maternal screening 22 57
Identified by maternal symptoms 3 2
No. of infants whose mothers had a CMV-specific 
increase in IgG by delivery/total no. tested 
5/8 13/19 1.00 ND
No. of infants whose mothers had an increase in 
CMV-specific IgG avidity by delivery/total 
no. tested 
8/8 19/19 1.00 ND
No. of infants whose mothers had an increase in 
CMV-specific IgG after HIG by infusion/to-
tal no. tested 
4/4 11/11 1.00 ND 
No. of infants whose mothers had a decrease in nat-
ural killer cells by delivery/total no. tested
2/8 8/14 0.63 ND 
Women who received HIG 6 31
No. of HIG doses per woman 0.08 0.75
Median 4 5
Interquartile range 3–5 4–6
Wk of gestation for HIG administration 0.08 0.59
Median 23 18
Interquartile range 20–27 15–22
Time between maternal infection and HIG 
administration — wk¶
6.7±1.9 6.6±2.8 0.78 ND
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veloped in premature newborns born to CMV-sero-
negative mothers after the receipt of blood prod-
ucts, whereas premature newborns born to CMV-
seropositive mothers became infected but remained
asymptomatic after receiving blood products. By
eight weeks of age, only 10 to 20 percent of mater-
nal antibody against CMV remains. Even at this age,
newborns are protected against severe CMV dis-
ease.
 
22
 
 Impressive results have also been observed
in pregnant guinea pigs challenged with guinea-
pig CMV before or after passive administration of
antiserum to either whole virus or to a specific
guinea-pig–CMV glycoprotein B that induces neu-
tralizing antibodies.
 
23,24
 
Because of the availability of serial serum sam-
ples from each subject, we could identify the time
of maternal infection for nearly all subjects to with-
in an average range of six weeks. The majority of
women were infected in the first trimester (42 per-
cent) or the second trimester (50 percent) of preg-
nancy. Thus, the possible efficacy of hyperimmune
globulin therapy for maternal infection in the last
trimester is uncertain. The infusion of hyperim-
mune globulin into amniotic fluid appeared ineffec-
tive. The pregnant woman who delivered the only
symptomatic neonate among all 68 treated women
received both intraamniotic and intra–umbilical-
cord hyperimmune globulin (Table 2).
Treatment with hyperimmune globulin de-
creased the number and percentage of both natu-
ral killer cells and HLA-DR+ cells, as compared with
these values among untreated women with active
CMV infection. This effect may be related to the
ability of hyperimmune globulin to inhibit the rep-
lication of CMV, since at the onset of a primary CMV
infection, the numbers of natural killer cells and
HLA-DR+ cells are increased.
 
25,26
 
 However, the in-
creased number and activity of these immune cells
are associated with a high level of production of cy-
tokines such as tumor necrosis factor 
 
a
 
, which can
contribute to immune-mediated fetal damage.
 
27,28
 
Thus, hyperimmune globulin may diminish the
pathogenic effects of CMV either by neutralization
or immunomodulatory effects.
Hyperimmune globulin appeared less effective
for the prevention of fetal infection than for the
treatment of fetuses already infected. Several fac-
tors may explain this finding. First, some of the six
 
* Values are geometric means (and 95 percent confidence intervals). HIG denotes hyperimmune globulin.
† P values were calculated with the use of a paired t-test on log-transformed data and are for the comparison of values 
either before and after treatment or at enrollment and at delivery.
‡ P<0.006 for the comparison with the untreated group. All other comparisons of IgG concentrations and avidity between 
the untreated group and the therapy and prevention groups either before or after treatment or at enrollment or delivery 
 
were not significantly different (P>0.05).
 
Table 5. CMV-Specific IgG Concentrations and CMV Avidity in Women before and after Hyperimmune Globulin (HIG) 
Infusions, at Enrollment, and at Delivery.*
Group
No. of Women 
with Results
CMV-Specific 
IgG Concentration P Value†
No. of Women 
with Results
CMV-Specific 
IgG Avidity P Value†
 
U/ml
% high-avidity
antibodies
 
Therapy group
 
Before HIG 10 5.5 (3.4–9.7) <0.001 13 11.1 (8.5–15.6) <0.001
After HIG 10 12.4 (8.0–19.0) 13 24.8 (18.6–31.4)
At enrollment 12 7.2 (5.0–11.4) <0.001 12 6.7 (4.1–10.6) <0.001
At delivery 12 17.4 (11.7–26.0)‡ 12 32.5 (29.3–41.7)
 
Prevention group
 
Before HIG 9 6.9 (3.7–12.7) <0.001 15 15.1 (12.7–18.0)‡ <0.001
After HIG 9 11.8 (7.5–18.5) 15 25.1 (19.8–31.7)
At enrollment 20 4.1 (2.8–6.1) <0.001 20 8.1 (5.5–12.0) <0.001
At delivery 20 11.7 (8.3–16.5) 20 29.6 (24.1–36.3)
 
Untreated group
 
At enrollment 17 6.6 (4.5–9.5) 0.54 17 8.7 (6.2–12.1) <0.001
At delivery 17 7.5 (4.9–11.4) 17 21.5 (15.3–30.1)
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
353;13
 
www.nejm.org september 
 
29, 2005
 
passive immunization against cmv during pregnancy
 
1361
 
infected infants may have been infected before their
mothers received hyperimmune globulin. Second,
the prevention group received a lower dose of hy-
perimmune globulin than the therapy group, al-
though it was administered monthly in the former
group to sustain antibody concentrations until de-
livery. Third and most likely is that the mechanism
of action of hyperimmune globulin differs in the
prevention and therapy groups. For the prevention
of fetal infection, hyperimmune globulin presum-
ably reduces maternal systemic or placental viral
loads, thus decreasing the likelihood of fetal infec-
tion. Once the fetus is infected, however, hyper-
immune globulin presumably reduces placental
or fetal inflammation, or both, resulting in increased
fetal blood flow with enhanced fetal nutrition and
oxygenation. This mechanism may also account
for the reversal of ultrasonographic abnormalities
apparently associated with hyperimmune globu-
lin therapy, since most signs and symptoms of con-
genital infection usually resolve during the first
weeks of life, presumably owing to improved nu-
trition and oxygenation. 
Serologic screening of asymptomatic women is
common in Europe but less so in the United States.
For our study, in 2000, we screened 1722 pregnant
women, 401 (23 percent) of whom were seronega-
tive and 31 (2 percent) of whom subsequently sero-
converted. In the United States, the seroconver-
sion rate is similar.
 
4,29
 
 Whether serologic screening
during pregnancy is desirable remains undecided.
Cost–benefit ratios need to be considered. Ultra-
sonography of the fetus at 20 weeks’ gestation is,
however, routine in many countries, including the
United States. Our experience suggests this is a sen-
sitive approach for predicting congenital disease
due to CMV.
A limitation of our study was that it did not in-
clude random assignment. Our data should stim-
ulate the initiation of randomized, controlled trials,
possibly in the United States or other countries
where maternal CMV screening is not routine, to
provide additional data and unequivocally estab-
lish the degree of efficacy of hyperimmune globu-
lin therapy and the optimal doses and dosing reg-
imens.
Although CMV-specific hyperimmune globulin
therapy was safe and appears to be associated with
both effective therapy and the prevention of con-
genital infection, passive immunization is not an
optimal solution. Our results indicate that active im-
munization is feasible. Several vaccines are being
evaluated in clinical trials, and a vaccine that induc-
es only maternal antibodies against CMV should be
effective in this setting.
 
30,31
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